Mainz Biomed Reports Results of 2024 Annual General Meeting
GlobeNewswire
BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics..
BERKELEY, Calif. and MAINZ, Germany, May 31, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics..
Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2..
*Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in..